[1] S.J. Felts, B.A. Owen, P. Nguyen, J. Trepel, D.B. Donner, D.O. Toft, The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. (2000), 275, 3305-3312.
[2] B.H. Kang, J. Plescia, T. Dohi, J. Rosa, S.J. Doxsey, D.C. Altieri, Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell (2007), 131, 257-70.
[3] H.K. Park, J.E. Lee, J. Lim, D.E. Jo, S.A. Park, P.G. Suh, B.H. Kang, Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim. BMC cancer (2014), 14, 431.
[4] H.K. Park, J.E. Lee, J. Lim, B.H. Kang, Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells. Mol. Cancer (2014), 13, 148.
[5] H.K. Park, J.H. Hong, Y.T. Oh, S.S. Kim, J. Yin, A.J. Lee, Y.C. Chae, J.H. Kim, S.H. Park, C.K. Park, M.J. Park, J.B. Park, B.H. Kang, Interplay between TRAP1 and Sirtuin-3 Modulates Mitochondrial Respiration and Oxidative Stress to Maintain Stemness of Glioma Stem Cells. Cancer research (2019), 79, 1369-1382.
[6] B.H. Kang, TRAP1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-targeted TRAP1 inhibitors. BMB Rep. (2012), 45, 1-6.
[7] Marco Sciacovelli, Giulia Guzzo, Virginia Morello, Christian Frezza, Liang Zheng, Nazarena Nannini, Fiorella Calabrese, Gabriella Laudiero, Franca Esposito, Matteo Landriscina, Paola Defilippi, Paolo Bernardi, Andrea Rasola, The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase, Cell Metabolism, Volume 17, Issue 6, 2013, Pages 988-999.
[8] Soichiro Yoshida, Shinji Tsutsumi, Guillaume Muhlebach, Carole Sourbier, Min-Jung Lee, Sunmin Lee, Evangelia Vartholomaiou, Manabu Tatokoro, Kristin Beebe, Naoto Miyajima, Robert P. Mohney, Yang Chen, Hisashi Hasumi, Wanping Xu, Hiroshi Fukushima, Ken Nakamura, Fumitaka Koga, Kazunori Kihara, Jane Trepel, Didier Picard, and Leonard Neckers, Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis, PNAS April 23, 2013 110 (17) E1604-E1612;
[9] Giulia Guzzo, Marco Sciacovelli, Paolo Bernardi, Andrea Rasola, Inhibition of succinate dehydrogenase by the mitochondrial chaperone TRAP1 has anti-oxidant and anti-apoptotic effects on tumor cells, Oncotarget. 2014; 5:11897-11908. https://doi.org/10.18632/oncotarget.2472
[10] Darong Kim, So-Yeon Kim, Dongyoung Kim, Nam Gu Yoon, Jisu Yun, Ki Bum Hong, Changwook Lee, Ji Hoon Lee, Byoung Heon Kang, Soosung Kang, Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models, Bioorganic Chemistry, Volume 101, 2020, 103901.
[11] J.T. Leonard, K. Roy, On selection of training and test sets for the development of predictive QSAR models, QSAR Comb. Sci. 25 (2006) 235.
[12] Ligprep, version 2.5, Schrödinger, LLC, New York, NY., 201223. Phase, version 4.4, Schrödinger, LLC, New York, NY., 2012
[13] Vivek Asati, Sanjay Kumar Bharti, Ashok Kumar Budhwani, 3D-QSAR and virtual screening studies of thiazolidine-2,4-dione analogs: Validation of experimental inhibitory potencies towards PIM-1 kinase, Journal of Molecular Structure, 1133, 2017, 278-293,
[14] Phase, version 4.4, Schrödinger, LLC, New York, NY., 2012
[15] S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, R.A. Friesner, PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results, J. Comput. Aided Mol. Des. 20 (2006) 647-71.
[16] M. Rajeswari, N. Santhi, V. Bhuvaneswari, Pharmacophore and virtual screening of JAK3 inhibitors, Bioinformation 10 (2014) 157-63.
[17] L. Crisan, A. Borota, A. Bora, L. Pacureanu, Diarylthiazole and diarylimidazole selective COX-1 inhibitor analysis through pharmacophore modeling, virtual screening, and DFT-based approaches, Struct. Chem. 30 (2019) 2311-26
[18] Phase 4.4 Quick Start Guide, Schrödinger, LLC, May 2013
[19] A.A. Sallam, W.E. Houssen, C.R. Gissendanner, K.Y. Orabi, A.I. Foudah, K.A. El Sayed, Bioguided discovery and pharmacophore modeling of the mycotoxic indole diterpene alkaloids penitrems as breast cancer proliferation, migration, and invasion inhibitors, Med. Chem. Comm. 4 (2013) 1360-69
[20] M.D. Hall, N.K. Salam, J.L. Hellawell, H.M. Fales, C.B. Kensler, J.A. Ludwig, G. Szakáes, D.E. Hibbs, M.M. Gottesman, Synthesis, activity, and pharmacophore development for isatinbeta- thiosemicarbazones with selective activity toward multidrug-resistant cells, J. Med. Chem. 52 (2009) 3191-3204
[21] M.K. Teli, G.K. Rajanikant, Pharmacophore generation and atom-based 3D-QSAR of Niso - propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors, Org. Med. Chem. Lett. 2 (2012) 1-10.
[22] P. Kamaria, N. Kawathekar, Ligand-based 3D-QSAR analysis and virtual screening in exploration of new scaffolds as Plasmodium falciparum glutathione reductase inhibitors, Med. Chem. Res. 23 (2013) 25-23
[23] A. Golbraikh, A. Tropsha, Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection, J. Comput. Aid. Mol. Des. 16 (2002) 357-369
[24] O.P. Tanwar, R. Saha, M.M. Alam, M. Akhtar, 3D-QSAR of amino-substituted pyrido [3,2B] pyrazinones as PDE-5 inhibitors. Med Chem Res. doi: 10.1007/s00044-010-9523-y
[25]http://gohom.win/ManualHom/Schrodinger_20152_docs/maestro/help_Maestro/phase/atom_based_qsar.html
[26] P. Kirubakaran, K. Muthusamy, K.H. Singh, S. Nagamani, Ligand-based pharmacophore modeling; atom-based 3D-QSAR analysis and molecular docking studies of phosphoinositide-dependent kinase-1 inhibitors, Indian J. Pharmaceut. Sci. 74 (2012) 141-51
[27] A. Dixit, S.K. Kashaw, S. Gaur, A.K. Saxena, Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist, Bioorg. Med. Chem. 12 (2004) 3591-98
[28] M.G. Shinde, S.J. Modi, V.M. Kulkarni, QSAR and molecular docking of phthalazine derivatives as epidermal growth factor receptor (EGFR) inhibitors, J. Appl. Pharm. Sci. 7 (2017) 181-91
[29] M. Clark, R.D. Cramer III, N. Van Opdenbosch, Validation of the general purpose Tripos 5.2 force field, J. Comp. Chem. 10 (1989) 982-1012
[30] Kaushik AC, Kumar S, Wei DQ and Sahi S (2018) Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes. Front. Chem. 6:23. doi: 10.3389/fchem.2018.00023
[31] Protein preparation wizard Schrödinger, LLC, New York, NY., 2012
[32] W.L. Jorgensen, D.S. Maxwell, J. Tirado-Rives, Development and testing of the OPLS all atom force field on conformational en ergetics of organic liquids, J. Am. Chem. Soc. 118 (1996) 11225-36
[33] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 23 (1997) 3-25
[34] A.K. Ghose, V.N. Viswanadhan, J.J. Wendoloski, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, J. Comb. Chem. 1 (1999) 55-68
[35] S.J. Teague, A.M. Davis, P.D. Leeson, T. Oprea, The design of leadlike combinatorial libraries, Angew Chem. Int. Ed. 38 (1999) 3743-8